These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32131665)

  • 21. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
    Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
    Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
    Mostafa NA; Eissa SS; Belal DM; Shoman SH
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer].
    Ying JM; Guo L; Liu XY; Qiu T; Lü N
    Zhonghua Yi Xue Za Zhi; 2010 Jun; 90(24):1674-7. PubMed ID: 20979875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-day FISH approach for the high-speed determination of HER2 gene copy status in breast carcinoma.
    Hegyi K; Lønborg C; Mónus A; Méhes G
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):567-71. PubMed ID: 23455187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation on parallel HER-2 testing using in situ hybridization and immunohistochemistry in breast cancer tissues].
    Pan XY; Gao HY; Zhang JL; Fu WT; Liu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2225-7. PubMed ID: 19923073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 overexpression of breast cancers in Hong Kong shows good concordance with HER2 amplification by fluorescence in-situ hybridisation study.
    Chan JK; Tsang WY; Lo ES; Wong MC
    Hong Kong Med J; 2008 Aug; 14(4):333; author reply 334. PubMed ID: 18685172
    [No Abstract]   [Full Text] [Related]  

  • 30. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
    Mrhalova M; Kodet R
    J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of her-2/neu by chromogenic in situ hybridization on borderline (2+) immunohistochemistry cases in carcinoma breast.
    Asif M; Khadim MT; Mushtaq S; Mamoon N; Akhtar F; Ali Z
    Asian Pac J Cancer Prev; 2011; 12(1):211-4. PubMed ID: 21517259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.
    Tubbs R; Pettay J; Skacel M; Powell R; Stoler M; Roche P; Hainfeld J
    Am J Pathol; 2002 May; 160(5):1589-95. PubMed ID: 12000711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
    Owens MA; Horten BC; Da Silva MM
    Clin Breast Cancer; 2004 Apr; 5(1):63-9. PubMed ID: 15140287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W; Nofech-Mozes S; Kahn HJ
    Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.